Molecular targeting therapies for neuroblastoma: Progress and challenges

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Neuroblastoma is the most common pediatric solid tumor, causing significant mortality.
• Tumor heterogeneity complicates current treatment efficacy.
• Understanding molecular pathogenesis is key to developing targeted therapies.

Purpose of the Study:

• To review current knowledge on molecular pathways and genetic aberrations in neuroblastoma.
• To provide an overview of preclinical and clinical molecular targeted therapies.
• To discuss future directions for novel therapeutic development.

Main Methods:

• Comprehensive literature review of high-throughput 'omics' studies.
• Analysis of genetic alterations (e.g., MYCN, BIRC5, PHOX2B, LIN28B).
• Evaluation of targeted therapies (e.g., ALK, MDM2, PI3K/Akt/mTOR, RAS-MAPK pathways, epigenetic regulators).

Main Results:

• Numerous genetic alterations and dysfunctional pathways drive neuroblastoma.
• Several molecular targets are under investigation for novel treatments.
• Combination therapies show promise for enhanced efficacy.

Conclusions:

• Targeting specific molecular pathways offers a promising avenue for neuroblastoma treatment.
• Further research into novel targets and combination strategies is essential.
• Improved therapies are needed to enhance survival rates for neuroblastoma patients.